$0.22 Earnings Per Share Expected for Amneal Pharmaceuticals Inc (NYSE:AMRX) This Quarter

Equities research analysts expect Amneal Pharmaceuticals Inc (NYSE:AMRX) to announce earnings of $0.22 per share for the current quarter, according to Zacks. Five analysts have made estimates for Amneal Pharmaceuticals’ earnings. The lowest EPS estimate is $0.20 and the highest is $0.27. Amneal Pharmaceuticals posted earnings per share of $0.24 during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.3%. The company is scheduled to announce its next earnings report on Thursday, August 8th.

On average, analysts expect that Amneal Pharmaceuticals will report full-year earnings of $0.95 per share for the current financial year, with EPS estimates ranging from $0.90 to $1.00. For the next financial year, analysts anticipate that the firm will report earnings of $1.15 per share, with EPS estimates ranging from $1.06 to $1.37. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). The company had revenue of $446.00 million during the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The firm’s revenue was up 4.9% on a year-over-year basis.

Several research firms recently commented on AMRX. SunTrust Banks began coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price target on the stock. ValuEngine downgraded shares of Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, April 5th. Zacks Investment Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a research note on Thursday, February 28th. Finally, Leerink Swann downgraded shares of Amneal Pharmaceuticals to a “market perform” rating in a research note on Friday, March 8th. One analyst has rated the stock with a sell rating, seven have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $18.64.

In other Amneal Pharmaceuticals news, SVP Joseph Todisco bought 15,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were acquired at an average price of $9.88 per share, with a total value of $148,200.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Andrew S. Boyer bought 19,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were acquired at an average cost of $9.46 per share, for a total transaction of $179,740.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 41,000 shares of company stock worth $387,300 in the last three months. Insiders own 26.34% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Cresset Asset Management LLC bought a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at about $29,000. Bessemer Group Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $34,000. NumerixS Investment Technologies Inc boosted its holdings in shares of Amneal Pharmaceuticals by 52.1% in the 1st quarter. NumerixS Investment Technologies Inc now owns 3,052 shares of the company’s stock valued at $42,000 after buying an additional 1,045 shares in the last quarter. Quantamental Technologies LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $68,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Amneal Pharmaceuticals by 28.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock valued at $91,000 after buying an additional 1,477 shares in the last quarter. Institutional investors and hedge funds own 36.05% of the company’s stock.

AMRX stock opened at $7.45 on Friday. The stock has a market capitalization of $2.28 billion, a P/E ratio of 7.84, a P/E/G ratio of 0.47 and a beta of 1.64. Amneal Pharmaceuticals has a 12 month low of $7.36 and a 12 month high of $24.48. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Story: Trading Strategy

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.